Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Fig. 3

Secondary efficacy endpoints (intention-to-treat population). a ACR20/50/70 response rates by study visit. b Mean change from baseline in DAS28–4(CRP) by study visit. Abbreviations: Adalimumab-EU adalimumab sourced from the European Union, ACR20/50/70 American College of Rheumatology 20%/50%/70% improvement, DAS28–4(CRP) Disease Activity Score-28: four components based on high-sensitivity C-reactive protein

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us